Free Trial

NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
5.03 million shs
Average Volume
600,149 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
NLSP stock logo

About NLS Pharmaceutics Stock (NASDAQ:NLSP)

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLSP Stock Price History

NLSP Stock News Headlines

NLS Pharmaceutics (NASDAQ:NLSP) Trading Up 9.8%
NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd Ordinary Shares
NLS Pharmaceutics Ltd Ordinary Shares NLSP
See More Headlines
Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.28 per share


Free Float
Not Optionable
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Alexander Zwyer M.B.A. (Age 55)
    President, CEO & Director
    Comp: $1.07M
  • Dr. George Apostol M.D. (Age 51)
    Chief Medical Officer and Global Head of Research & Development
    Comp: $154k
  • Dr. Eric Konofal M.D. (Age 57)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Ms. Elena Thyen-Pighin
    Chief Financial Officer
  • Dr. Christian C. Wenger Dr. iur. (Age 60)
    L.L.M., Ph.D., General Counsel

NLSP Stock Analysis - Frequently Asked Questions

Should I buy or sell NLS Pharmaceutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLSP, but not buy additional shares or sell existing shares.
View NLSP analyst ratings
or view top-rated stocks.

How have NLSP shares performed in 2024?

NLS Pharmaceutics' stock was trading at $0.5899 on January 1st, 2024. Since then, NLSP stock has decreased by 70.4% and is now trading at $0.1745.
View the best growth stocks for 2024 here

Are investors shorting NLS Pharmaceutics?

NLS Pharmaceutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 45,400 shares, an increase of 182.0% from the April 30th total of 16,100 shares. Based on an average daily volume of 839,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are sold short.
View NLS Pharmaceutics' Short Interest

When is NLS Pharmaceutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our NLSP earnings forecast

When did NLS Pharmaceutics IPO?

NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLSP) was last updated on 5/28/2024 by Staff

From Our Partners